| 101 |
31127319 | Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer. | 2019 Jul |
1 |
| 102 |
31178493 | Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma. | 2019 Sep 15 |
2 |
| 103 |
31256210 | Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. | 2019 Oct |
8 |
| 104 |
31260890 | Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors. | 2019 Oct 1 |
2 |
| 105 |
31313100 | Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. | 2019 Aug |
4 |
| 106 |
31382035 | Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors. | 2019 Nov |
1 |
| 107 |
31382924 | ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib. | 2019 Aug 5 |
3 |
| 108 |
31388026 | Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity. | 2019 Aug 6 |
2 |
| 109 |
31399568 | The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. | 2019 Aug 9 |
6 |
| 110 |
31416808 | Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. | 2019 Dec 15 |
2 |
| 111 |
31447007 | Clinical significance of ROS1 5' deletions in non-small cell lung cancer. | 2019 Sep |
3 |
| 112 |
31463126 | Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis. | 2019 Jul |
1 |
| 113 |
31584608 | Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. | 2019 Dec 1 |
1 |
| 114 |
31639374 | ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. | 2019 Nov 15 |
3 |
| 115 |
31717403 | Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems. | 2019 Nov 8 |
1 |
| 116 |
31720561 | Targeted therapies for ROS1-rearranged non-small cell lung cancer. | 2019 Oct |
1 |
| 117 |
27606884 | Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report. | 2018 Feb |
1 |
| 118 |
28844392 | Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation. | 2018 Jan |
1 |
| 119 |
28893136 | Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations. | 2018 Sep |
1 |
| 120 |
28971587 | Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review. | 2018 Jan |
1 |
| 121 |
29187012 | Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. | 2018 Jan |
3 |
| 122 |
29343973 | A patient with classic biphasic pulmonary blastoma harboring CD74-ROS1 fusion responds to crizotinib. | 2018 |
4 |
| 123 |
29352732 | Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. | 2018 May |
2 |
| 124 |
29361925 | Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report. | 2018 Jan 23 |
1 |
| 125 |
29371790 | Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report. | 2018 |
3 |
| 126 |
29437595 | Integrated molecular profiling of juvenile myelomonocytic leukemia. | 2018 Apr 5 |
3 |
| 127 |
29477381 | CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib. | 2018 May 28 |
6 |
| 128 |
29501208 | [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?] | 2018 Apr |
2 |
| 129 |
29517860 | CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing. | 2018 May |
2 |
| 130 |
29576302 | Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion. | 2018 Apr |
1 |
| 131 |
29596029 | Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. | 2018 May 10 |
4 |
| 132 |
29610289 | E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. | 2018 Apr |
3 |
| 133 |
29663378 | Tyrosine kinase receptor c-ros-oncogene 1 inhibition alleviates aberrant bone formation of TWIST-1 haploinsufficient calvarial cells from Saethre-Chotzen syndrome patients. | 2018 Sep |
2 |
| 134 |
29704675 | Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. | 2018 Jul |
5 |
| 135 |
29738763 | 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. | 2018 Jun 22 |
6 |
| 136 |
29805713 | Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations. | 2018 |
3 |
| 137 |
29910649 | Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. | 2018 Jun |
1 |
| 138 |
29961337 | Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. | 2018 Jul 1 |
2 |
| 139 |
29981925 | The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. | 2018 Nov |
2 |
| 140 |
30025202 | Identification and biological evaluation of glycol diaryl ethers as novel anti-cancer agents through structure-based optimization of crizotinib. | 2018 Dec |
2 |
| 141 |
30029601 | Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report. | 2018 Jul 20 |
3 |
| 142 |
30049378 | Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion. | 2018 Aug |
1 |
| 143 |
30053332 | Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. | 2018 Oct |
4 |
| 144 |
30083883 | A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. | 2018 Sep |
3 |
| 145 |
30095326 | A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. | 2018 |
2 |
| 146 |
30144837 | Tissue and Blood Biomarkers in Lung Cancer: A Review. | 2018 |
1 |
| 147 |
30212301 | Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer? | 2018 Sep 13 |
1 |
| 148 |
30258534 | Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib. | 2018 Sep 13 |
3 |
| 149 |
30327756 | Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. | 2018 Aug |
1 |
| 150 |
30410351 | Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. | 2018 |
5 |